Results 21 to 30 of about 7,553 (206)

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases

open access: yesМедицинская иммунология, 2023
Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina   +4 more
doaj   +1 more source

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

open access: yes, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant   +49 more
core   +2 more sources

BTK (Bruton agammaglobulinemia tyrosine kinase) [PDF]

open access: yesAtlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on BTK (Bruton agammaglobulinemia tyrosine kinase), with data on DNA, on the protein encoded, and where the gene is implicated.
Hendriks, RW, van, Loo PF
openaire   +2 more sources

Bruton tyrosine kinase inhibitors for multiple sclerosis

open access: yesNature Reviews Neurology, 2023
Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated worsening of disability, which is assumed to be mainly associated with transient infiltration of peripheral immune cells into the central nervous system (CNS). However, approved therapies are less effective at slowing disability accumulation in patients with MS ...
Julia Krämer   +3 more
openaire   +2 more sources

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

open access: yes, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani   +59 more
core   +1 more source

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

open access: yesPLoS ONE, 2017
Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton's tyrosine kinase and phosphoinositide 3-kinase δ offer ...
Anella Yahiaoui   +9 more
doaj   +1 more source

A covalent BTK ternary complex compatible with targeted protein degradation

open access: yesNature Communications, 2023
Bridging covalent ligand discovery with chimeric degrader design has emerged as a mechanism to target proteins that lack enzymatic activity or are intractable.
James Schiemer   +8 more
doaj   +1 more source

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

open access: yesHaematologica, 2015
Chronic lymphocytic leukemia is a malignancy of mature auto-reactive B cells. Genetic and functional studies implicate B-cell receptor signaling as a pivotal pathway in its pathogenesis.
Adrian Wiestner
doaj   +1 more source

Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism [PDF]

open access: yes, 2015
© 2015 Wiley Periodicals, Inc. Acknowledgement Grant sponsor: State of Lower Saxony-Israel Research Cooperation; Grant number: ZN2035; Grant sponsor:German Research Council; Grant number: SFB/TRR43 and FOR1336; Grant sponsor: Parkinson UK; Grant number ...
Akarasereenont   +92 more
core   +1 more source

Switching immune signals on and off

open access: yeseLife, 2015
Bruton's tyrosine kinase, an enzyme that is important for B cell function, can be activated in a number of ways.
Nam Chu, Philip A Cole
doaj   +1 more source

Home - About - Disclaimer - Privacy